Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671411 | 1.00 | CA12 (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL15670460 | 0.84 | CA12 (0.74) | CA12CA1CA2CA3CA4 | |
| SCHEMBL15670461 | 0.84 | CA12 (0.74) | CA12CA1CA2CA3CA4 | |
| SCHEMBL8514186 | 0.84 | CA12 (0.74) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1576885 | 0.84 | ITGA4 (0.43) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1576807 | 0.83 | FOLH1 (0.49) | CA1CA2CA7CA9 | |
| SCHEMBL30673429 | 0.82 | MMP2 (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL19450068 | 0.82 | POLB (0.51) | TLR2PSMB5 | |
| SCHEMBL5653982 | 0.80 | PDCD1 (0.49) | — | |
| SCHEMBL1576808 | 0.80 | PDCD1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853453-B2 | Processes for reducing impurities in lacosamide | RANBAXY LABORATORIES LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-20130204042-A1 | PROCESSES FOR REDUCING IMPURITIES IN LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | US | disclosed |
| US-20130085304-A1 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-04 | — | — | US | disclosed |
| US-8378142-B2 | Intermediate compounds and their use in preparation of lacosamide | RANBAXY LABORATORIES LIMITED (IN) | 2013-02-19 | — | — | US | disclosed |
| EP-2501674-A2 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | Ranbaxy Laboratories Limited (IN) | 2012-09-26 | — | — | EP | disclosed |
| US-8093426-B2 | 2-tritylamino-3-(hydroxy or methoxy)propionic acid, or corresponding benzylamide thereof as chemical intermediate; chirally pure lacosamide; high purity | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| EP-2067765-A2 | Intermediate compounds and their use in preparation of lacosamide | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130204042-A1 | PROCESSES FOR REDUCING IMPURITIES IN LACOSAMIDE | HEXA, NPEPPS, RNPEP | CA12 103/4885CA1 415/4885CA2 198/4885 |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
| US-20130085304-A1 | PROCESSES FOR PREPARATION OF POLYMORPHIC FORMS OF LACOSAMIDE | BDNF, FKBP1B, SCN5A | CA12 321/4885CA1 46/4885CA2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.